Stock Doctor uses its defined “9 Golden Rules if Investing” methodology which has a demonstrated track record of outperformance over the long term. Its quantitative process has undergone significant back testing which has been further enhanced over the research and investment product’s nearly 30-year history. Stock Doctor also includes a qualitative overlay via its team of analysts who conduct a bottom-up fundamental review before a company is eligible to receive ‘Star Stock’ status.
There really isn’t a “secret sauce” behind these stories – it is purely a matter of scouring the market for companies displaying solid fundamentals (which we define as our “Golden Rules”), and then allowing these businesses to compound both earnings and cash flows over many, many years.
Pilbara Minerals Ltd (ASX: PLS) and IGO Ltd (ASX: IGO) have reported record profits, leading to mountains of cash sitting on balance sheets, and outsized dividends returned to shareholders.
Following the Invocare takeover, the Propel Funeral Partners Ltd (ASX:PFP) share price could be ripe for the picking.
The Australian share market or ASX index is uniquely known for its high dividend yield. On average, the ASX has a yield more than double that of the US S&P 500!
Sociedad Quimica y Minera de Chile (NYSE: SQM) is the world’s second-largest producer of lithium chemicals. Its 2Q23 report stunned the market by missing analyst profit expectations by ~20%, sending its shares lower.
Over the past 5 days, the GUD Holdings Limited (ASX: GUD) share price has jumped 12.5%. But that’s no surprise to the team at Stock Doctor. Analyst Daniel Ortisi explains why this week’s news means for GUD shareholders.
The Cochlear Limited (ASX: COH) share price bounced dramatically higher this week following a bumper report. But is the Cochlear share price looking a little expensive? Stock Doctor’s Daniel Ortisi weighs in.
The Commonwealth Bank of Australia (ASX: CBA) share price jumped after reporting results. But was it really a good result for CBA shareholders? Stock Doctor’s Daniel Ortisi takes a deep look.
The team at Stock Doctor initiated coverage of ARF as a Star Income Stock in 2017 at a share price of $2.18. With a forward yield of ~4.6%, the shares don’t look obviously cheap, but we feel that this is a fair price to pay given the long runway of rental growth ahead.
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
